These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38467309)

  • 1. Uncoupling of Cytochrome P450 2B6 and stimulation of reactive oxygen species production in pharmacogenomic alleles affected by interethnic variability.
    Yamoune S; Müller JP; Langmia IM; Scholl C; Stingl JC
    Biochim Biophys Acta Gen Subj; 2024 May; 1868(5):130595. PubMed ID: 38467309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.
    Zanger UM; Klein K
    Front Genet; 2013; 4():24. PubMed ID: 23467454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.
    Wang PF; Neiner A; Kharasch ED
    Anesthesiology; 2018 Oct; 129(4):756-768. PubMed ID: 30085944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
    Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
    Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
    Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
    Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
    Wang PF; Neiner A; Kharasch ED
    Drug Metab Dispos; 2020 Jun; 48(6):438-445. PubMed ID: 32238417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
    Talakad JC; Kumar S; Halpert JR
    Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
    Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
    Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
    Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.
    Wang J; Sönnerborg A; Rane A; Josephson F; Lundgren S; Ståhle L; Ingelman-Sundberg M
    Pharmacogenet Genomics; 2006 Mar; 16(3):191-8. PubMed ID: 16495778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C; Ogburn ET; Guo Y; Desta Z
    Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation.
    Tran AX; Ho TT; Varghese Gupta S
    J Clin Pharm Ther; 2019 Apr; 44(2):174-179. PubMed ID: 30578565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PharmVar GeneFocus: CYP2B6.
    Desta Z; El-Boraie A; Gong L; Somogyi AA; Lauschke VM; Dandara C; Klein K; Miller NA; Klein TE; Tyndale RF; Whirl-Carrillo M; Gaedigk A
    Clin Pharmacol Ther; 2021 Jul; 110(1):82-97. PubMed ID: 33448339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
    Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
    Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
    Wang PF; Neiner A; Kharasch ED
    Drug Metab Dispos; 2019 Oct; 47(10):1195-1205. PubMed ID: 31324697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.
    Pearce RE; Gaedigk R; Twist GP; Dai H; Riffel AK; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2016 Jul; 44(7):948-58. PubMed ID: 26608082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.
    Gao LC; Liu FQ; Yang L; Cheng L; Dai HY; Tao R; Cao SP; Wang D; Tang J
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1205-1213. PubMed ID: 27439448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.